Affordable Access

deepdyve-link
Publisher Website

Development of an Insulin Pen is a Patient-Centric Multidisciplinary Undertaking: A Commentary.

Authors
  • Sparre, Thomas1
  • Hansen, Niels-Aage B1
  • Wernersson, Anya Sonia1
  • Guarraia, Mark1
  • 1 Novo Nordisk A/S, Søborg, Denmark. , (Denmark)
Type
Published Article
Journal
Journal of Diabetes Science and Technology
Publisher
SAGE Publications
Publication Date
May 01, 2022
Volume
16
Issue
3
Pages
617–622
Identifiers
DOI: 10.1177/19322968211058707
PMID: 34852662
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The goal of human-centered insulin pen design is to relieve the treatment burden of a chronic condition and help affected individuals to feel free of disease. The patient as well as their entire ecosystem should be considered. At Novo Nordisk A/S, we believe that embedding human-centered design at the heart of our development processes is best achieved with multidisciplinary experts in-house to work alongside product development teams and, importantly, the end user. Novo Nordisk introduced the first commercially available insulin pen in 1985 and has continued to develop reusable/durable and prefilled insulin pens to meet different patient needs, through to the latest NovoPen 6 and NovoPen Echo Plus with SMART technology. Human-centered design is essential for delivering meaningful and practical solutions for individuals with diabetes.

Report this publication

Statistics

Seen <100 times